NVO
Novo Nordisk
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
NVO Profile
Novo Nordisk A/S
A leading global healthcare company that develops insulin analogues, human insulin, and oral antidiabetic drugs for diabetes care
Pharmaceutical
Invalid Date
07/09/1981
New York Stock Exchange
76,302
12-31
Depository Receipts (Ordinary Shares)
Novo Alle 1, DK-2880 Bagsverd, Denmark
Development and sales of diabetes medical products
Novo Nordisk A/S was established in 1989 by the merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. The company is a global healthcare company and a global leader in diabetes and obesity care. The company has a broad portfolio of diabetes and obesity care and rare disease products, including glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity, modern insulin and human insulin.